Aclarion, Inc. (NASDAQ:ACON) shares are trading higher premarket on Monday after the company disclosed a commercial partnership with Scripps Health in San Diego, CA.
This agreement will introduce Nociscan to Southern California and to the top spine specialists at Scripps Green and Scripps Health.
Notably, Scripps Health is a nonprofit healthcare system that operates five hospitals and 19 outpatient facilities, serving half a million patients annually with the support of 2,600 affiliated physicians.
Ryan Bond, Chief Strategy Officer of Aclarion. “We are pleased to bring Nociscan to Scripps Health and the millions of people throughout Southern California. Dr. Eastlack and his colleagues will now be able to utilize Nociscan in clinic and within on-going research trials, both of which are vitally important to their mission of advancing spine care.”
Last month, the company announced it secured funding for its CLARITY trial of its diagnostic tool, Nociscan.
Also, Aclarion identified Northwestern Medicine as the first site for the pivotal CLARITY trial, which aims to showcase Nociscan’s clinical and economic benefits in spine surgery.
Price Action: ACON shares are up 84.8% at $6.19 premarket at the last check Monday.
Read Next:
- AST SpaceMobile Teams Up with Vodafone For Satellite Broadband Service Across Europe
Photo: One Photo via Shutterstock.
